Ending 2025, I wrote with optimism about the status of CytomX Therapeutics ( CTMX ) probody treatment approach to cancer, despite rises in market sentiment throughout the year. Now they have reportedI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in t ...